CD19 and non-Hodgkin lymphoma: Between May 2016, and March 2020, 124 patients with r/r CD19 positive malignancies were enrolled to the trial, including 41 (35%) patients with ALL, 71 (60%) with NHL, four (3%) with Richter’s transformation and two (2%) with acute myeloid leukemia (AML).